MYGN - Myriad Genetics, Inc.
| Previous Close | 28.41 |
| Open | 28.50 |
| Bid | 28.70 x 800 |
| Ask | 28.70 x 2200 |
| Day's Range | 27.80 - 28.94 |
| 52 Week Range | 20.10 - 48.40 |
| Volume | 591,663 |
| Avg. Volume | 1,047,212 |
| Market Cap | 2.134B |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
- Zacks
Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
- Investor's Business Daily
This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval
Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.
- Barrons.com
Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground
Wall Street is set for a sleepy open Monday with stock futures indicating modest gains across all three indexes. The Dow Jones Industrial Average, S&P 500 and Nasdaq Compositewere all set to open up 0.1% as of 8:20 a.m. in what is expected to be a quiet day for trading. (AZN) (ticker: AZN) and (MRK) (MRK) were up 0.6% and 0.2%, respectively, after Lynparza, the ovarian-cancer drug they market, won approval by the Food and Drug Administration to be used to treat advanced pancreatic cancer.
- MarketWatch
Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer
Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza. BRACAnalysis CDx is the only FDA-approved genetic test for this indication. Lynparza is marketed by AstraZeneca PLC and Merck & Co. Inc. . "The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments," said Ruth March, head of precision medicine at AstraZeneca. Myriad Genetics's stock has lost 7.9% year to date through Friday, while the S&P 500 has gained 29%.
- TheStreet.com
Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test
The Food and Drug Administration approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.
- Simply Wall St.
Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance?
It hasn't been the best quarter for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, since the share price has fallen...
- Barrons.com
Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing
Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.
- Insider Monkey
Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN)
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]
- Zacks
Myriad Genetics Presents Trial Outcomes in Breast Health
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
- Insider Monkey
Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks
Is Tri Pointe Group Inc (NYSE:TPH) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market […]
- Zacks
Myriad Genetics Reports Favorable Study Result on Prequel
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
- Zacks
Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- MarketWatch
Myriad shares fall despite positive results on prenatal test
Shares of Myriad Genetics dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis. Myriad said that Prequel, which uses whole-genome sequencing, can help reduce the need for expensive procedures like amniocentesis or chorionic villus sampling. Sales of its prenatal business, which makes up about 12% of total revenues, rose 5% to $23.5 million in the most recent quarter, up from $18.1 million in the same period a year ago. Myriad's stock has tumbled 14% year-to-date. The S&P 500 is up 24%.
- Zacks
Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
- PR Newswire
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Myriad Genetics, Inc. (NASDAQ: MYGN) securities between September 2, 2016 to August 13, 2019 (the "Class Period"). Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Zacks
Myriad Genetics' Test Added in Disease Activity Measure List
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
- Zacks
Myriad Genetics Presents New Test Data in Autoimmune Segment
Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.
- Simply Wall St.
Independent Chairman John Henderson Just Bought Shares In Myriad Genetics, Inc. (NASDAQ:MYGN)
Investors who take an interest in Myriad Genetics, Inc. (NASDAQ:MYGN) should definitely note that the Independent...
- Thomson Reuters StreetEvents
Edited Transcript of MYGN earnings conference call or presentation 4-Nov-19 9:30pm GMT
Q1 2020 Myriad Genetics Inc Earnings Call
- Investor's Business Daily
This Genetic-Testing Stock Plummeted 40% On A Massive Earnings Miss
Shares of Myriad Genetics crashed Tuesday after the genetic-testing company missed fiscal first-quarter estimates and slashed its full-year outlook. It blamed an administrative change.
- Zacks
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
- MarketWatch
Myriad Genetics stock plunges to lead premarket losers after earnings miss by wide margin
Shares of Myriad Genetics Inc. plummeted 35% to pace all premarket decliners, after the molecular diagnostics company reported fiscal first-quarter results that were well below expectations and slashed its full-year outlook. The company reported late Monday a net loss for the quarter to Sept. 30 of $20.6 million, or 28 cents a share, after a loss of $700,000, or 1 cent a share, in the year-ago period. Excluding non-recurring items, such as stock-based compensation expenses and acquisition-related charges, adjusted earnings per share came to 8 cents, below the FactSet consensus of 31 cents. Revenue fell 7.9% to $186.3 million, missing the FactSet consensus of $202.3 million. "We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the deletion of the historical hereditary cancer CPT codes," said Chief Executive Mark Capone. The company cut its fiscal 2020 guidance ranges for adjusted EPS to $1.00 to $1.10 from $1.80 to $1.90 and for revenue to $800 million to $810 million from $865 million to $875 million. The stock had gained 21% year to date through Monday, while the S&P 500 has advanced 23%.
- Barrons.com
Uber Stock, Shake Shack Are Falling as the Dow Chugs Ahead Again
STOCKSTOWATCHTODAY BLOG U.S. stock futures were higher Tuesday morning. And third-quarter earnings reports had several companies’ shares moving in premarket trading. Dow Jones Industrial Average futures were up 0.
